The Centre for the Advancement of Sustainable Medical Innovation (CASMI) has been commissioned by the Innovative Medicines Initiative (IMI) to explore and define the remit of a stakeholder platform to improve the impact of IMI projects. IMI is a public-private partnership between EFPIA and the European Union that aims to advance pharmaceutical R&D in Europe and patient access to innovative medicines. IMI was launched in 2008 and the IMI2 programme has a budget of €3.3 billion for the period 2014-2024.
Following a 9-month programme of work we are now ready to present a number of IMI case studies and project results that are considered relevant for further exploitation through stakeholder engagement, as we move towards finalising our thinking for a broader stakeholder platform. One of the lenses through which we have viewed these projects is Medicines Adaptive Pathways for Patients (MAPPs), which includes the concept of Adaptive Licensing, as it represents a comprehensive, alternative development pathway for medicines that is enabled by advances in pharmaceutical science
A Stakeholder Platform was held in London on 20th October 2014 where leading academics, clinicians and industry were brought together to discuss (i) the challenges inherent in converting real-world outputs to outcomes, and solutions to these challenges; (ii) how IMI can contribute towards to the broader MAPPs agenda; and (iii) how best to engage stakeholders in current and future IMI projects.
The Stakeholder Platform was a lively success and we hope to have a report published by the end of the year.
For more information on the project, contact Emily Algar